Rivaroxaban also decreased the risk for total venous thromboembolism or all result in death as well as for key venous thromboembolism or venous thromboembolism connected death . Compared with enoxaparin, dabigatran was not linked to a several possibility of symptomatic deep vein thrombosis or pulmonary embolism . Dabigatran was connected with a trend in the direction of a larger risk of complete venous thromboembolism or all trigger death than enoxaparin plus a similar danger of important venous thromboembolism or venous thromboembolism linked death . The chance of total venous thromboembolism or all cause death was similar between dabigatran 220 mg and enoxaparin but it was increased together with the dabigatran 150 mg dose than with enoxaparin . Serious venous thromboembolism or venous thromboembolism connected death did not vary significantly between the dabigatran 220 mg every day dose v enoxaparin or between the dabigatran 150 mg day-to-day dose v enoxaparin . Apixaban decreased the risk of symptomatic deep vein thrombosis in contrast with enoxaparin but was related to a numerical boost in cases of pulmonary embolism with borderline heterogeneity .
The results for pulmonary embolism were homogeneous within the two pivotal research on total knee replacement surgical treatment , during which the danger of symptomatic pulmonary embolism with apixaban was drastically increased than that with enoxaparin . Around the contrary, apixaban was connected to a lower possibility of complete venous thromboembolism or Trametinib selleck chemicals all result in death along with a trend towards a lower threat of main venous thromboembolism or venous thromboembolism linked death than enoxaparin. . Main security final result Rivaroxaban was linked to a substantial increase in danger of clinically pertinent bleeding . Dabigatran didn’t demonstrate a significant increase in contrast with enoxaparin . The possibility was comparable while in the comparison of dabigatran 220 mg with enoxaparin Entinostat and dabigatran 150 mg with enoxaparin . On the contrary, apixaban was connected to a drastically decreased threat of clinically related bleeding compared with enoxaparin . No proof of statistical heterogeneity was discovered for this outcome amongst scientific studies comparing rivaroxaban, dabigatran, or apixaban with enoxaparin. Secondary safety outcomes Rivaroxaban was related to a non-significant trend in the direction of a larger danger of leading bleeding than was enoxaparin and clinically relevant non-major bleeding . In contrast with enoxaparin, dabigatran was linked to a comparable danger of leading bleeding along with a non-significant trend in the direction of a larger possibility of clinically related non-major bleeding . Apixaban showed a non-significant trend in the direction of a reduced risk of big bleeding than did enoxaparin , which was during the restrict of statistical significance for clinically pertinent non-major bleeding . No substantial trends had been discovered in danger of death involving the new anticoagulants and enoxaparin.